Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Tesofensine: Final Phase IIb data

In the double-blind, Danish Phase IIb TIPO-1 trial in 203 patients, all 3 doses of tesofensine met the primary endpoints of significant improvements

Read the full 234 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE